GeoffreyIraShapiroMDPhD

PubMed

• 331 citations
  Institutional implementation of clinical tumor profiling on an unselected cancer population
  Lynette M. Sholl, Khanh T. Do, Priyanka Shivdasani, Ethan Cerami, Adrian M. Dubuc
  JCI Insight. 2016-11-17
• 661 citations
  KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.
  David S. Hong, Marwan Fakih, John H. Strickler, Jayesh Desai, G. Durm
  The New England Journal of Medicine. 2020-09-20
• 164 citations
  Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.
  Panagiotis A. Konstantinopoulos, William T. Barry, Michael J. Birrer, Shannon N. Westin, Karen Cadoo
  The Lancet. Oncology. 2019-04-01

Journal Articles

• KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors  
  David S Hong, Marwan G Fakih, Gregory A Durm, Geoffrey I Shapiro, Gerald S Falchook, Adrian Sacher, Crystal S Denlinger, John C Krauss, Andrew L Coveler, Suresh S Rama..., The New England Journal of Medicine
• Institutional Implementation of Clinical Tumor Profiling on an Unselected Cancer Population  
  Khanh Do, Lauren L Ritterhouse, William C Hahn, Geoffrey I Shapiro, Barrett J Rollins, Neal I Lindeman, Alanna Church, Geoffrey R Oxnard, Bruce E Johnson, Frank C Kuo,..., The Journal of Clinical Investigation
• Clinical development of the CDK4/6 inhibitors abemaciclib and ribociclib in breast cancer  
  Barroso-Sousa, Shapiro GI and Tolaney S.M., Breast Care, 1/1/2016
• Phase I safety, pharmacokinetic and pharmacodynamics study of the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with irinotecan in pa...  
  LoRusso PM, Li J, Burger A, Heilbrun LK, Sausville EA, Boerner SA, Smith D, Pilat MJ, Zhang J, Tolaney SM, Cleary JM, Chen AP, Rubinstein L, Boerner JL, Bowditch A, Ca..., Clin Cancer Res, 1/1/2016
• Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors  
  Patnaik A, Rosen SR, Tolaney SM, Tolcher AW, Goldman JW, Gandhi L, Papdopoulos KP, Beeram M, Rasco DW, Hilton JF, Nasir A, Beckmann RP, Schade AE, Fulford AD, Nguyen T..., Cancer Discov, 1/1/2016
• ASP9853, an inhibitor of inducible nitric oxide synthase dimerization, in combination with docetaxel: preclinical investigation and a Phase I study in advanced solid t...  
  Luke JJ, LoRusso P, Shapiro GI, Krivoshik A, Schuster R, hyamazaki T, Arai Y, Fakhoury A, Dmuchowski C, Infante JR, Cancer Chemother Pharmacol, 1/1/2016
• Targeting CDK4 and CDK6: from discovery to therapy  
  Sherr CJ, Beach D, Shapiro GI, Cancer Discov, 1/1/2016
• The BRCA1-?11q alternative spliceisoform bypasses germline mutations and promotes therapeutic resistance to PARP inhibition and cisplatin  
  Wang Y, Bernhardy AJ, Cruz C, Krais JJ, Nacson J, Nicolas E, Peri S, van der Gulden H, van der Heijden I, O'Brien SW, Zhang Y, Harrell MI, Johnson SF, Candido Dos Reis..., Cancer Res, 1/1/2016
• Incoporation of next-generation sequencing into routine clinical care to direct treatment of head and neck squamous cell carcinoma  
  Chau NG, Li YY, Jo VY, Rabinowits G, Lorch JH, Tishler RB, Margalit DN, Schoenfeld JD, Annino DJ, Goguen L, Thomas T, Becker H, Haddad R, Krane JF, Lindeman NI, Shapir..., Clin Cancer Res, 1/1/2016
• Phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with advanced solid tumors  
  Sarantopoulos J, Shapiro GI, Cohen RB, Clark JW, Kauh JS, Weiss GJ, Cleary JM, Mahalingam D, Pickard MD, Faessel H, Berger AJ, Burke K, Mulligan G, Dezube BJ, Harvey RD, Clin Cancer Res, 1/1/2016
• A phase 1 study of ABT-806 in subjects with advanced solid tumors  
  Cleary JM, Reardon DA, Azad N, Gandhi L, Shapiro GI, Chaves J, Pdersen M, Ansell P, Ames W, Xiong H, Munashinghe W, Dudley M, Reilly EB, Holen K, Humerickhouse R, Invest New Drugs, 1/1/2015
• A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung canc...  
  Ramalingam S, Goss G, Rosell R, Schimd-Bindert G, Zaric B, Andric Z, Bondarenko I, Komov D, Ceric T, Khuri F, Samarzija M, Felip E, Ciuleanu T, Hirsh V, Wehler T, Spic..., Ann Oncol, 1/1/2015
• Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer  
  Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D'Andrea AD, Cancer Discov, 1/1/2015
• Cutaneous keratocanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor beta by the monoclonal antibody fresolimumab (GC1008)  
  Lacouture ME, Morris JC, Lawrence DP, Tan AR, Olencki TE, Shapiro GI, Dexube BJ, Berzofsky JA, Hsu FJ, Guitart J, Cancer Immunol Immunother, 1/1/2015
• Intratumoral heterogeneity in EGFR-mutant NSCLC results in divergent resistance mechanisms in response to EGFR tyrosine kinase inhibition  
  Soucherary M, Capelletti M, Pulido I, Kuang Y, Paweletz CP, Becker JH, Kikuchi E, Xu C, Patel TB, Al-Shahrour F, Carretero J, Wong KK, Janne PA, Shapiro GI, Shimamura T, Cancer Res, 1/1/2015
• DNA-PK: a candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival  
  Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L, Willoughby CE, Telvantou D, Thomas HD, Jackson J, Burd AD, Newell D, Rose J, Manas DM, Shapiro GI, Curtin NJ, Ree..., Clin Cancer Res, 1/1/2015
• A phase I dose-finding study in patients with solid malignancies of the oral gamma-secretase inhibitor PF-03084014  
  Messersmith WA, Shapiro GI, Cleary JM, Jimeno A, Dasari A, Huang B, Shaik N, Cesari R, Zheng X, Reynolds JM, English PA, MacLachlan KR, Kern KA, Lorusso PM, Clin Cancer Res, 1/1/2015
• First-in-human study of PF-05212384 (PKI-587), a small-molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer  
  Shapiro GI, Bell-McGuinn KM, Molina JR, Bendell JC, Spicer J, Kwak EL, Pandya SS, millham R, Borzillo G, Pierce KJ, Han L, Houk BE, Gallo JD, Alsina M, Brana I, Tabern..., Clin Cancer Res, 1/1/2015
• First-in-human phase I dose escalation study of a second-generation non-ansamycin HSP90 inhibitor AT13387 in patients with advanced solid tumors  
  Shapiro GI, Kwak E, Dezube BJ, Yule M, Ayrton J, Lyons J, Mahadevan D, Clin Cancer Res, 1/1/2015
• A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors  
  Jones SF, Siu LL, Bendell JC, Cleary JM, Razak AR, Infante JR, Pandya SS, Bedard PL, Pierce KJ, Houk B, Roberts WG, Shreeve SM, Shapiro GI, Invest New Drugs, 1/1/2015
• Phase II study of tivantinib (ARQ197) in patients with metastatic triple-negative breast cancer  
  Tolaney SM, Tan S, Guo H, Barry W, Van Allen E, Wagle N, Brock J, Larrabee K, Paweletz C, Ivanova E, Janne P, Overmoyer B, Wright JJ, Shapiro GI, Winer EP, Krop IE, Invest New Drugs, 1/1/2015
• Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor  
  Tap WD, Wainberg ZA, Anthony SP, Ibrahim PN, Zhang C, Healey JH, Chmielowski B, Staddon AP, Cohn AL, Shapiro GI, Keedy VL, Singh AS, Puzanov I, Kwak EL, Wagner AJ, Von..., New Engl J Med, 1/1/2015
• Crizotinib as salvage and maintenance with allogeneic stem cell transplantation for refractory anaplastic large cell lymphoma  
  Cleary JM, Rodig S, Barr PM, Shinagare AB, Clark JW, Shapiro GI, Armand P, J Natl Compr Cancer Network, 1/1/2014
• Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib  
  Wagle N, Grabiner BC, Van Allen EM, Hodis E, Jacobus S, Supko JG, Stewart M, Choueiri TK, Gandhi L, Cleary JM, Elfiky AA, Taplin ME, Stack EC, Signoretti S, Loda M, S..., Cancer Discov, 1/1/2014
• Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance  
  Chen Z, Akbay E, Mikse O, Tupper T, Cheng K, Wang Y, Tan X, Altabef A, Woo SA, Chen L, Reibel JB, Janne PA, Sharpless NE, Engelman JA, Shapiro GI, Kung AL, Wong KK, Cancer Res, 1/1/2014
• Join now to see all

Books/Book Chapters

• PARP inhibitors for cancer therapy. 
  Chapter: Disruption of DNA repair by cell cycle and transcriptional CDK inhibition. 
  Page 413 - 430Cornell L, Johnson N, Shapiro GIEditors: NJ Curtin and RA Sharma.Humana Press2015

Abstracts/Posters

• GSK525762, a selective bromodomain (BRD) and extra termina protein (BET) inhibitor: results from part 1 of a phase I/II open-label single-agent study in patients with...
  O’Dwyer PJ, Piha-Paul S, French C, Harward S, Ferron-Brady G, Wu Y, Barbash O, Wyce A, Annan M, Horner T, Parr NJ, Prinjha RK, Carpenter C, Shapiro G, Dhar A, Hann C, Proc Amer Assoc Cancer Res, 1/1/2016
• Phase 2 study of nivolumab in metastatic leiomyosarcoma of the uterus.
  George S, Barysauskas CM, Solomon S, Tahlil K, Malley R, Hohos M, Polson K, Loucks M, Wagner AJ, Merriam P, Morgan JA, Rodig SJ, Hodi SF, Shapiro G, Demetri GD, J Clin Oncol, 1/1/2016
• In vivo synergism between PARP inhibitor olaparib and HSP90 ihibitor AT13387 in high-grade serous ovarian cancer patient-derived xenografts.
  Konstantinopoulos P, Palakurthi S, Zeng Q, Zhou S, Liu JF, Ivanova E, Paweletz C, Kommajosyula N, D’Andrea AD, Shapiro G, Matulonis UA, J Clin Oncol, 1/1/2016
• A Phase 1 study of MLN0128 and bevacizumab in patients with recurrent glioblastoma or other solid tumors.
  Nayak L, Hays JL, Muzikansky A, Gaffey SC, Do KT, Puduvalli VK, Lee EQ, Rinne ML, Norden AD, Beroukhim R, Wen PY, Doyle LA, Chen HX, Shapiro G, Reardon D, J Clin Oncol, 1/1/2016
• Evaluation of a spray-dried dispersion (SDD) formulation of MGCD265, a receptor tyrosine kinase (RTK) inhibitor, in a phase 1 study of patients with advanced solid tum...
  Sharma S, Shapiro G, Kollmannsberger CK, Christensen J, Tassell VR, Faltaos D, Chao RC, Hurwitz H, J Clin Oncol, 1/1/2016
• Single-agent LV305 to induce anti-tumor immune and clinical responses in patients with advanced or metastatic sarcoma and other cancers expressing NY-ESO-1.
  Somaiah N, Block MS, Kim JW, Shapiro G, Do KT, Hwu P, Eder JP, Jones RL, Gnjatic S, Lu H, Ter Meulen J, Hsu FJ, Pollack S, J Clin Oncol, 1/1/2016
• Phase 1 study of sapacitabine and seliciclib in patients with advanced solid tumors.
  Tolaney SM, Hilton JF, Clear JM, Gandhi L, Kwak EL, Clark JW, Wolanski A, Bell TD, Rodig SJ, Chaio JH, Blake D, Shapiro G, J Clin Oncol, 1/1/2016
• IPI-549-01: A phase 1/1b first-in-human study of IPI-549, a PI3K-gamma inhibitor, as monotherapy in combination with pembrolizumab in subjects with advanced solid tumors.
  Tolcher AW, Hong DS, Sullivan RJ, Mier JW, Shapiro G, Pearlberg J, Brail LH, Kharidia J, Han L, Ullmann CD, Stern HM, Wolchock JD, J Clin Oncol, 1/1/2016
• Phase I study of the PI3K/mTOR inhibitor gedatolisib (PF-05212384) in combination with docetaxel, cisplatin and dacomitinib.
  Wainberg ZA, Shapiro G, Curigliano G, Kristeleit S, Leong S, Alsina M, Milella M, Britten CD, Gelmon KA, Olszanski AJ, Vaishampayan UN, Lopez-Martin JA, Kern KA, Pierc..., J Clin Oncol, 1/1/2016
• Phase I study of the PI3K?/? inhibitor AZD8186 in patients with advanced castration-resistant prostate cancer, triple-negative breast cancer, squamous non-small-cell l...
  Shapiro GI, American Association for Cancer Research meeting, Philadelphia, PA, 1/1/2015
• Evaluatioin of the MET/AXL receptor tyrosine kinase inhibitor MGCD265 in a patient with metastatic non-small cell lung cancer harboring AXL amplification.
  Do, K, MacConnaill L, Dubuc AM, Chen I, Chao R, Tassell V, Chistensen J, Shapiro GI, Sholl LM, Proc. 16th World Conference on Lung Cancer, 1/1/2015
• Combination of the PARP inhibitor veliparib (ABT888) with irinotecan (CPT-11) in patients with triple-negative breast cancer (TNBC): preliminary activity and signature...
  LoRusso PM, Tolaney SM, Wong S, Parchment RE, Kinders RJ, Wang L, Aldrich J, Chen A, Durecki D, Boerner SA, Guthrie T, Bowditch A, Heilbrun LK, Pilat MJ, Craig D, Cai ..., Proc Am Assoc Cancer Res, 1/1/2015
• Clinical efficacy of the BET bromodomain inhibitor TEN-010 in an open-label substudy with patients with documented NUT-midline carcinoma.
  Shapiro GI, Dowlati A, LoRusso PM, Eder JP, Anderson A, Do KT, Kagey MH, Sirard C, Bradner JE, Landau SB, Proc AACR-NCI-EORTC, 1/1/2015
• A phase 1, open-label multiple dose escalation trial to determine safety and tolerability of once daily OPB-111077 in subjects with advanced cancer.
  Cote G, Papadopoulos K, Patnaik Am, Rascoe D, Smith L, Bullock A, Flaherty K, Shapiro G, Berlin J, Monga M, Habermann T, Witzig T, Lin C, Tsai L-F, Elekes A, Ohi N, Ta..., Proc AACR-NCI-EORTC, 1/1/2015
• Phase 1/2 study of oral rucaparib: final phase 1 results.
  Kristeleit RS, Burris HA, LoRusso P, Patel MR, Asghar US, El-Khouly F, Calvert AH, Infante JR, Hilton JF, Tolaney SM, Kittaneh M, Giodano H, Borrow J, Jaw-Tsai SS, Sha..., J Clin Oncol, 1/1/2014
• A phase I study of the single-agent CDK4/6 inhibitor LEE011 in patients with advanced solid tumors and lymphomas.
  Infante JR, Shapiro G, Witteveen P, Gerecitano JF, Ribrag V, Chugh R, Issa I, Chakraborty A, Matano A, Zhao X, Parasuraman S, Cassier P, J Clin Oncol, 1/1/2014
• Efficacy and safety of crizotinib in patients with advanced c-MET amplified non-small cell lung cancer.
  Camidge DR, Ou S-HI, Shapiro G, Otterson GA, Villaruz LC, Villalona-Calero MA, Iafrate AJ, Varella-Garcia M, Dacic S, Cardarella S, Zhao W, Tye L, Stephenson P, Wilner..., J Clin Oncol, 1/1/2014
• A phase 1 first-in-human study of XMT-1107, a polymer-conjugated fmagillol derivative, in patients with advanced solid tumors.
  Bendell JC, Shapiro G, Sausville EA, Jones SF, Hilton JF, Shkolny D, Blank B, Berstrom DA, J Clin Oncol, 1/1/2014
• Phase 1 multicenter, open label, dose-escalation study of LEE011, an oral inhibitor of cyclin-dependent kinase 4/6, in patients with advanced solid tumors or lymphomas.
  Infante JR, Shapiro GI, Witteveen PO, Gerecitano JF, Ribrag V, Chugh R et al, Proc AACR-NCI-EORTC, 1/1/2013
• A first-in-human phase I study of ZSTK474, an oral pan-PI3K inhibitor, in patients with advanced solid malignancies.
  Lockhart AC, Olszanski AJ, Allgren RL, Yaguchi S, Cohen SJ, Hilton JF, Wang-Gillam A, Shapiro GI, Proc AACR-NCI-EORTC, 1/1/2013
• Identification of factors governing sensitivity of NSCLC cell lines to inhibition of poly(ADP-ribose) polymerase.
  Kommajosyula N, Cao Y, Moreau L, D'Andrea A, Shapiro GI, Proc AACR, 1/1/2013
• The CDK inhibitor dinaciclib sensitizes triple-negative breast cancer cells to PARP inhibition.
  Johnson SF, Johnson N, Chi D, Primack B, D’Andrea AD, Lim E, Shapiro GI, Proc AACR, 1/1/2013
• Combination of the MEK inhibitor, pimasertib (MSC 1936369B), and the PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: results of a phase Ib dose...
  Infante JR, Gandhi L, Shapiro G, Rizvi N, Burris HA, Bendell JC, Baselga J, Hsu K, von Richter O, Locatelli G, Asatiani E, Heist RS, Proc AACR, 1/1/2013
• A phase I, dose-escalation, safety, pharmacokinetic, pharmacodynamic study of thioureidobutyronitrile, a novel p53 targeted therapy, in patient with advanced solid tum...
  Shapiro G, Supko JG, Cho DC, Hilton JF, Hadfield M, Pruitt-Thompson S, Bordoli-Trachsela E, Zvereva N, Wolanski A, Sato-DiLorenzo A, Gotthardt S, Fox EA, Verselis SJ, ..., J Clin Oncol, 1/1/2013
• A phase I dose-escalation and PK study of continuous oral rucaparib in patients with advanced solid tumors.
  Kristeleit RS, Shapiro G, LoRusso P, Infante JR, Flynn M, Patel MR, Tolaney SA, Hilton JF, Calvert AH, Giordano H, Isaacson JD, Borrow J, Allen AR, Jaw-Tsai SS, Burris HA, J Clin Oncol, 1/1/2013
• Join now to see all

Lectures

• Developmental Therapeutics and Tumor Biology (Nonimmuno) 
  ASCO Annual Meeting 2019 - Chicago, IL - 6/4/2019
• Preliminary Results of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Two Phase IIa Dose Expansion Cohorts in Relapsed/Refractory TP53 Wild-Type ... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Trial design of a first-in-human phase 1 evaluation of SY-1365, a first-in-class selective CDK7 inhibitor, with initial expansions in ovarian and breast cancer. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• Phase 1 Clinical Trial Designs 
  1/1/2016
• Conduct of Phase 1 Clinical Trials 
  1/1/2016
• FDA Investigational Drug Applications 
  1/1/2016
• Advances in Cancer Drug Development 
  1/1/2016
• Targeting CDK4/6 and MEK in KRAS-driven non-small cell lung cancer 
  Washington, DC - 1/1/2016
• Phase 1 trial of first-in-class ATR inhibitor VX-970 in combination with cisplatin in patients with advanced solid tumors (NCT02157792). 
  New Orleans, LA - 1/1/2015
• Cyclin-dependent kinases and CD7 as Therapeutic Targets 
  Paris, France - 1/1/2015
• Beyond CDK4/6: Development of Cell Cycle and Transcriptional CDK Inhibitors 
  San Antonio, TX - 1/1/2015
• Clinical Development of CDK4/6 inhibitors 
  Tufts University, Medford, MA - 1/1/2015
• Drugging the Cell Cycle in Cancer Introductory Lecture 
  San Diego, CA - 1/1/2014
• CDK4/6 Inhibition: cellular outcomes, synthetic lethal interactions with oncogene activation, and clinical development of selective compounds 
  San Diego, CA - 1/1/2014
• Biology of CDK4/6 Inhibition 
  Washington, DC - 1/1/2014
• Cancer Medicine and Hematology 
  1/1/2014
• Novel Therapeutic Opportunities for CDK and PARP Inhibition in Cancer 
  MGH Cancer Center - 1/1/2014
• Experimental Therapeutics Clinical Trials Network (ETCTN): Clinical and Translational Researcher Perspective 
  National Cancer Institute, Bethesda, MD - 1/1/2014
• Clinical Trials Symposium Introductory Lecture 
  Washington, DC - 1/1/2013
• Translational Studies with CDK and PARP Inhibitors 
  Vanderbilt University, Nashville, TN - 1/1/2013
• CDK Inhibition: A novel strategy for extending PARP inhibition to HR-proficient TNBCs 
  Washington, DC - 1/1/2013
• The HSP90 Inhibitor AT13387 
  Santa Monica, CA - 1/1/2013
• PARP Inhibition in Lung Cancer 
  Santa Monica, CA - 1/1/2013
• Targeting Homologous Recombination: Translational Studies of CDK and PARP inhibitors 
  San Antonio, TX - 1/1/2013
• Clinical Developent of Selective CDK4/6 Inhibitors in Breast Cancer 
  Dana-Farber Cancer Institute, Boston, MA - 1/1/2013
• Join now to see all

Other

• Small molecule inhibitors of cyclin-dependent kinases. In: M.V. Blagosklonny, editor. Cell Cycle Checkpoints and Cancer. 
  Shapiro GI, Landes Bioscience
  Georgetown, TX - 1/1/2001
• Thesis: Influenza virus gene expression: viral RNA replication in vivo and in vitro. 
  Shapiro GI, Weill-Cornell Graduate School of Medical Sciences,
  Cornell University - 1/1/1987